Browse News
Filter News
Found 3 articles
-
Once dormant due to a lack of commercial success and drug side effects, the radiopharmaceutical space is gaining momentum in the form of increased investment and scientific advances.
-
Bayer will nab exclusive rights to a differentiated alpha radionuclide, actinium-225 investigational compound, and a small molecule targeting prostate-specific membrane antigen.
-
Bayer Acquires Noria and PSMA Therapeutics to Expand Pipeline in Prostate Cancer
6/3/2021
Bayer today announced that it has entered into an agreement to acquire Noria Therapeutics Inc. (Noria) and PSMA Therapeutics Inc.